Beneficial Effect of Adding Pentoxifylline to Processed Semen Samples on ICSI Outcome in Infertile Males

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the effect of pentoxifylline used in preparation of semen samples that will be used for ICSI in infertile men complaining of mild and moderate asthenozoospermia (i.e. cases which does not need motility enhancement prior to ICSI) in comparison to semen samples without pentoxifylline preparation on the outcome of ICSI.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Therapeutic Effect of Co-administration of Pentoxifylline and Zinc in Men With Idiopathic Asthenozoospermia

NCT05178953

Men Infertility

UNKNOWN EARLY_PHASE1

ICSI Using Pentoxifylline to Identify Viable Spermatozoa in Absolute Asthenozoospermia Patients

NCT05943353

in Vitro Fertilization

UNKNOWN NA

Effect of Pentoxifylline and Zinc Co-administration in Patients With Oligoasthenoteratozoospermia

NCT05156684

Idiopathic Infertility

UNKNOWN NA

Sperm DNA Damage to Intracytoplasmic Sperm Injection Outcome

NCT03129243

Infertility, Male

COMPLETED

Cytokines Supplementation to Culture Media and ICSI Outcome

NCT04547699

ICSI

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary outcome measures were the number of oocytes retrieved, the number of oocytes injected, number of oocytes fertilized, fertilization rate, number of embryos and their quality (G1: good embryos, G2: fair embryos and G3: bad embryos), number of embryos transferred (ET), number of embryo sacs, embryo implantation rate, pregnancy rate and abortion rate for all 3 groups and pregnancy rate and abortion rate for both group (I) and group (II).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pentoxifylline Allergy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pentoxifylline

effect of pentoxifylline on ICSI outcome

Group Type OTHER

effect of pentoxifylline on ICSI outcome

Intervention Type OTHER

semen processing with pentoxifylline prior to ICSI

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

effect of pentoxifylline on ICSI outcome

semen processing with pentoxifylline prior to ICSI

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* seeking ICSI for infertility

Exclusion Criteria

* Pyospermia, presence of antisperm antibodies. Azoospermia, severe male factor, severe asthenozoospermia. Past history of orchitis. Patients who received empirical treatment for asthenozoospermia e.g. oral Pentoxifylline, l-carnitine or antioxidants during the past 3 to 6 month. Diabetics, hypertensives or patients with any other chronic systemic illnesses. Wife's age more than 35 years. Low antral count. Presence of any ovarian factor contributing to infertility e.g. polycystic ovaries.

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No